Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SASPject SP1.13
- Development stage
- Preclinical
- Lead developer
- SASPiPhi
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
SASPject SP1.13 is an engineered, non-lytic bacteriophage therapeutic being developed by SASPiPhi for the treatment of endocarditis caused by *Staphylococcus aureus*. Utilizing SASPiPhi's proprietary SASPject platform, the therapy employs a modified bacteriophage as a nano-delivery vehicle to deliver a gene encoding a small acid-soluble spore protein (SASP) directly into target bacterial cells. Once inside, the host bacterial machinery synthesizes the SASP, which binds to and inactivates bacterial DNA, leading to rapid cell death. SASPject SP1.13 is currently in the lead optimization stage of preclinical development.
02
Targets
Neuraminidase
Beyond the preview
Go deeper on SASPject SP1.13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SASPject SP1.13.